Drug Trial Radar · NCT06717074
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 28, 2024
Primary completion
Apr 29, 2026
Study completion Apr 29, 2026
Sponsor
- Lead sponsor
- Ribocure Pharmaceuticals ABIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety of drug RBD4059, and also if drug RBD4059 works to treat stable coronary artery disease in adults. The main questions the trial aim to answer are: What medical problems may participants experience when taking drug RBD4059? Researchers will compare drug RBD4059 to a placebo to see if drug RBD4059 works to treat stable coronary artery disease. Participants will: Receive drug RBD4059 or a placebo. Visit the clinic 11 or 12 times during 11 or 14 months for checkups and tests, depending on which treatment group they belong to.
Conditions
- Stable Coronary Artery Disease CAD
Interventions
RBD4059Drug
RBD4059, active drug.
PlaceboDrug
Placebo that is identical in appearance and volume to the doses of active IMP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, intensity and seriousness of reported AEs, SAEs and AEs of special interest (AESIs) during the trial.Time frame: From baseline until end of trial at week 48 or 60, depending on the dose group.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ribocure Clinic
Mölndal, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.